Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London

blonca9
Aug 31, 2024
1 min read

Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for ATTR-CM, and clarifies market confusion around a data point that was presented yesterday.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight